12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

MiSeqDx Cystic Fibrosis Diagnostic Assay regulatory update

Illumina said on its 4Q12 earnings call that it submitted 510(k) applications to FDA for the MiSeqDx genome sequencing system and its MiSeqDx Cystic Fibrosis Diagnostic Assay. MiSeqDx is a benchtop sequencer that allows for...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >